Sienna Cancer Diagnostics (ASX:SDX)
Company Profile
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Sienna Cancer Diagnostics.
RELATED STOCKHEAD STORIES
Check up: Pot, takeovers, and COVID-19 are making investors happy
Lunchtime ASX Small Cap Wrap: Who wants to hear the good news today?
Bard1 makes Sienna an offer it can’t refuse: a $45m merger
10 at 10: These 10 ASX stocks are primed for Easter this morning
Health Kick Podcast: Learning from the Swine flu pandemic, the market potential of exosome therapeutics and jumping ASX life-sciences hurdles
Trading Places: The substantial holders that were buying and selling this week
Cancer Wars Part 2: These are the ASX small cap diagnostics plays that want to conquer cancer
Lunchtime ASX small cap wrap: Who’s started an intergenerational war today?
Health: Smiles bites down as it reveals an investigation into the ex-CEO’s behaviour
Sienna is selling its pee testers in South Korea to sniff out bladder cancer
Fliers, flameouts and fakers: what happened in biotechland in 2018
IPO Watch: who’s going ahead, who’s on hold and who’s missing in action
Sienna looks to $7bn cancer diagnostics market
